LungArchives
Three-dimensional analysis to predict recurrence of pure-solid non-small cell lung cancer after segmentectomy
Lung 4 min.
The Japan Clinical Oncology Group 0802 (JCOG 0802) recently conducted a pivotal randomized controlled trial [1] that compared the non-small cell lung cancer (NSCLC) survival rates of lobectomies and segmentectomies for tumors less than 2 cm in diameter. These findings highlighted the value of the segmentectomy...
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
Lung 1 min.
Squamous non-small-cell lung cancer (NSCLC) is associated with worse clinical outcomes than non-squamous NSCLC, but treatment options are scarce. We aimed to evaluate the efficacy and safety of ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as a first-line therapy for patients with...
Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial
Lung 1 min.
Limertinib is a new third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. This study aimed to prospectively assess the efficacy and safety of limertinib versus gefitinib as a first-line treatment for locally advanced or metastatic non-small-cell lung cancer (NSCLC) with...
The lung immune prognostic index stratifies the occurrence of checkpoint inhibitor pneumonitis in advanced non-small cell lung cancer patients: a multi-institutional cohort study
Lung 4 min.
Advanced non-small-cell lung cancer (NSCLC) is a formidable malignancy associated with a poor prognostic outlook, typically manifesting with notably low 1-year and 5-year overall survival rates [1]. Advanced NSCLC often loses the opportunity for curative surgery at the time of diagnosis [2]. Recently,...
